2026 ICD-10-CM Diagnosis Code C39.0Malignant neoplasm of upper respiratory tract, part unspecified

ICD-10-CM Codes›C00–D49›C30-C39›C39

ICD-10-CM C39.0
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

C39.0 is a billable ICD-10-CM diagnosis code for malignant neoplasm of upper respiratory tract, part unspecified. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 11 through 13, 146 through 148. Coders also document this condition as malignant neoplasm of upper respiratory tract. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Respiratory cancers.

For Medicare Advantage risk adjustment, C39.0 maps to CMS-HCC Category 21 (Lymphoma and Other Cancers) under the V28 model, adding a risk factor of about 0.671 for a community, non-dual, aged beneficiary in payment year 2026.

Code Identity

ICD-10-CM Code
C39.0
Billable Status
Yes — Valid for Submission
Code Describes
Malignant neoplasm of upper respiratory tract, part unspecified
Short Description
Malignant neoplasm of upper respiratory tract, part unsp
Parent Code
C39
Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs

Code Classification

ChapterC00–D49Neoplasms
SectionC30-C39Malignant neoplasms of respiratory and intrathoracic organs
CategoryC39Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs
This CodeC39.0Malignant neoplasm of upper respiratory tract, part unspecified

Medicare Risk Adjustment (HCC)Billing

C39.0 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.

CMS-HCC V28 Category (Payment Model)
HCC 21— Lymphoma and Other Cancers
Payment HCC · PY 2026 one of 463 ICD-10-CM codes in this category
Risk Adjustment Factor (RAF) Weight
+0.671
community, non-dual, aged · ranges 0.493–0.739 across segments
Hierarchy
Superseded by HCC 17, HCC 18, HCC 19, and HCC 20
a more severe related category takes the payment when both are reported
Prior Model (CMS-HCC V24)
HCC 11
V24 retired V28 pays 100% of MA risk scores since PY 2026
Other CMS Models
PACE (CMS-HCC V22): HCC 11 · ESRD (V21): HCC 11 · ESRD (V24): HCC 11
ESRD V21 weights: 0.076 dialysis, 0.284–0.298 functioning graft · ESRD V24 weights: 0.059 dialysis, 0.257–0.362 functioning graft
Part D (RxHCC)
RxHCC 22 — Prostate, Breast, Bladder, and Other Cancers and Tumors
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Malignant neoplasm of upper respiratory tract
  • Primary malignant neoplasm of upper respiratory tract

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO022
Respiratory cancers
Default principal diagnosis: inpatient Yes · outpatient Yes

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary		Malig.
Secondary		Ca
in situ		BenignUncertainUnspec.
respiratory › tract NEC › upperC39.0C78.30D02.4D14.4D38.5D49.1

Patient EducationClinical

Cancer

Cancer is not just one disease but many diseases. Cancer begins in your cells, which are the building blocks of your body. Usually, your body forms new cells as needed, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should.

The full article covers:

  • What is cancer?
  • What are the types of cancer?
  • How does cancer develop?
  • What are the symptoms of cancer?
  • How is cancer diagnosed?
  • What are the treatments for cancer?
  • Can cancer be prevented?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C39.0 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
165.0 Mal neo upper resp NOS
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About C39.0Overview

What is the ICD-10 code for malignant neoplasm of upper respiratory tract, part unspecified?

The ICD-10-CM code for malignant neoplasm of upper respiratory tract, part unspecified is C39.0 (sometimes written as C390). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Is C39.0 a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of upper respiratory tract, part unspecified on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does C39.0 group to?

When malignant neoplasm of upper respiratory tract, part unspecified is the principal diagnosis on an inpatient stay, it groups to MS-DRG 11, 12, 13, 146, 147, 148, with relative weights from 0.7971 to 5.4541 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of C39.0?

Under the General Equivalence Mappings, malignant neoplasm of upper respiratory tract, part unspecified converts to ICD-9-CM 165.0 (mal neo upper resp NOS). The mapping is a direct match.

What HCC is C39.0?

C39.0 (malignant neoplasm of upper respiratory tract, part unspecified) maps to CMS-HCC Category 21 (Lymphoma and Other Cancers), commonly written as HCC 21, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 11 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.

Does C39.0 risk-adjust for Medicare Advantage payment?

Yes. When documented and reported on a Medicare Advantage encounter, C39.0 adds a risk adjustment factor of about 0.671 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.493 to 0.739 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, and HCC 20) supersedes it when both are reported. See the full factor table on the HCC 21 category page.